Investors have great interest in Celsius Holdings Inc. (CELH), Zosano Pharma Corporation (ZSAN)

Celsius Holdings Inc. (NASDAQ: CELH) shares are 340.89% up in the year-to-date (YTD) period and have moved -0.45% or -$0.1 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +558.39% lower. Comparatively, the stock is -20.78% down YTD and 136.87% over the trailing 3-month period. If we look at the shorter duration, its week performance is -1.05% and 46.36% over the month.

Analyst Recommendations

On February 01, 2018, Maxim Group recommended the CELH stock is a Buy, while earlier, ROTH Capital had Initiated the stock as a Buy on April 30, 2020. 4 analysts offering the recommendations for the stock have a consensus rating of 1.70 to suggest that the CELH stock is a “Strong Buy. 0 of the 4 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.

The stock currently trades at $21.20 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $25.38. The forecasts give the Celsius Holdings Inc. stock a price target range of $27.00 on the higher side while at least one analyst think the stock could plunge to a low of $23.50. The two limits represent an upside potential of 21.48% or 9.79%.

Earnings Forecast

Analysts estimate the earnings to increase 300.00% in the current quarter to $0.02, down from the $0.03 reported in the same quarter a year ago. For the current year, earnings should grow to an average of $0.08, up 66.60% from $0.16 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0 and $0.05. Wall Street estimates earnings per share to be at an average of $0.18 for the next year.

Insider Transactions Summary

According to SEC data, total insider shares purchases at the company stands at 22 over the last 12 months, while SEC filings reveal that there have been 5 insider sales over the same period. Insiders have purchases 10,623,583 shares while those sold by company executives and officers stand at 135,000. The last 3 months have seen insiders trade a total of 87,442 and 10,000 in purchases and sales respectively.

Zosano Pharma Corporation (NASDAQ:ZSAN), on the other hand, is trading around $1.65 with a market cap of $124.80M and analyst research firms have a negative stance on its shares. Some analysts are even forecasting -$0.6 per share in earnings this year on a short term (1 year) basis.

Let us briefly look at the Zosano Pharma Corporation (ZSAN) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.

Company balance sheet and cash flow

ZSAN’s operating expenses over the recent quarter were at $7000.0. This represented a 100.09% of the company’s total revenues which amounted $7.7 million. With this in place, we can see that the company’s diluted EPS declined -$0.14 on the year-over-year period, shrinking to -$0.55 as given in the last earnings report.

In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $47.71 million from $55.34 million over the previous quarter. The cash flow from operating activities totaled -$16.44 million, significantly higher than the -$18.61 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$21.15 million.

Insider activity

Insiders have transacted a total of 10 times at Zosano Pharma Corporation over the last 6 months, with insider purchases undertaken 10 times and accounting for 247,500 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 10.0 shares. Insiders now hold a total of 158.43k shares after the latest sales, with -277.90% net shares purchased.

Major holders

Insiders own 0.50% of the company shares, while shares held by institutions stand at 14.20%. Investors are also buoyed by the number of investors in a company, with Zosano Pharma Corporation having a total of 32 institutions that hold shares in the company.